News

CPDC Cancer Imaging Research Programs Receive Renewed Funding of $2.9 Million from OICR

Investment acknowledges groundbreaking progress and provides CPDC with additional resources to continue work to bring new radiopharmaceuticals for personalized cancer diagnosis and treatment to clinical use in Ontario.

HAMILTON ON and LONDON ON, (April 23, 2012)—Cancer research in Ontario, aimed at developing the next generation of radiopharmaceuticals, received a financial boost today. The Centre for Probe Development and Commercialization (CPDC) received a new four-year investment from the Ontario Institute for Cancer Research (OICR) of more than $2.9 million. The funding will enable CPDC to continue its groundbreaking work in developing and commercializing new radiopharmaceuticals that will help physicians to improve the non-invasive diagnosis and staging of cancer, select the best targeted therapies, assess the effectiveness of treatment in days rather than months, and improve outcomes for adult and pediatric cancer patients.

Radiopharmaceutical for Targeted Treatment of Prostate Cancer to Enter Clinical Trials

Canadian centre of excellence partners with US-based Molecular Insight Pharmaceuticals to manufacture a new radiopharmaceutical for clinical trials that will evaluate the potential to deliver targeted radiotherapy directly to metastatic prostate cancer.

HAMILTON, ON, CANADA and CAMBRIDGE, MA, USA. (January 30, 2012)—A new targeted radiopharmaceutical, designed to deliver a therapeutic dose of radiation directly to metastatic prostate cancer, will be manufactured in Hamilton, Ontario to be used in clinical trials that will evaluate its efficacy and benefits for patients. The radiopharmaceutical, I-131-MIP-1466, will be manufactured by the Centre for Probe Development and Commercialization (CPDC, Hamilton, ON), for the developer of the compound, US-based Molecular Insight Pharmaceuticals (Molecular Insight, Cambridge, MA).

Joint Venture Announced to Expand Use of Molecular Imaging in Ontario for Patient Care and Research of Cancer and Other Serious Diseases

CanProbe focuses on developing new radiopharmaceuticals to meet growing Canadian and global demand for advanced diagnostic and therapeutic molecular probes.

TORONTO, ON (June 22, 2011)-CanProbe, a unique, not-for-profit joint venture to advance the use of medical isotopes for diagnosing and treating cancer and other serious diseases, was announced today by the Centre for Probe Development and Commercialization (CPDC) and the University Health Network (UHN).

CPDC Joins National Project to Develop Alternative Sources of Medical Isotopes

Non-reactor-based production of medical isotopes could provide Canadians with back-up or supplementary supplies and ease disruptions to patient scans.

Hamilton, ON (January 24, 2011) – The Centre for Probe Development and Commercialization (CPDC) joined the Government of Canada today to announce a national project to develop alternative sources of medical isotopes that could help to secure a reliable, long-term supply for Canadians.

CPDC CEO, Scientific Director among Top 40 Under 40

A McMaster University professor, working on the next generation of molecular imaging probes for the early detection of disease, has been named one of Canada’s Top 40 Under 40.

TORONTO, ON (June 7, 2010) John Valliant, associate professor in the departments of Chemistry and Medical Physics, and CEO and scientific director of the Centre for Probe Development and Commercialization (CPDC), was included in the annual list of exceptional people, published in today’s edition of The Globe and Mail.

CPDC Scientific Director delivers SNM opening plenary lecture

TORONTO, ON (June 19, 2009) Challenging times are shaping the future of molecular imaging probe development and nuclear medicine, according to the CPDC’s John Valliant. Valliant, PhD, scientific director and CEO at the CPDC, spoke at the Society of Nuclear Medicine’s Annual Meeting in Toronto on June 14, 2009, where he urged scientists to be innovative and not to rely on already established approaches and targets.